Market Report Source

Overview

Targeted therapies are the top selling class of cancer drug, reaching sales of nearly $15 billion in the seven major pharmaceutical markets in 2007. The high growth of this therapy class makes it attractive to drug developers, resulting in 10 new entrants to the market since 2005. More drugs are likely to gain approval in the near future, contributing to a rapidly changing competitive landscape.

Scope of this report:

• Forecast sales of every marketed targeted therapy cancer brand in each of the seven major markets over the period 2007 to 2017
• Analysis and segmentation of the market at various levels including drug class, indication, company and mode of administration
• Comprehensive brand profiles and analysis, including approval dates, patent expiries and all key events likely to impact sales
• Snapshot of the targeted therapy cancer brands market in the rest of the world

Research and analysis highlights:

The targeted therapy cancer brands market is rapidly expanding and is forecast to maintain a high growth rate over the forecast period. The market will reach a value of over $42 billion by 2017 in the seven major pharmaceutical markets, growing at a CAGR of 11%

Approvals in new tumor types with high unmet need, use in earlier treatment settings and growing physician familiarity are among the factors likely to drive sales of the best performing targeted therapy brands. However, pharmacoeconomic pressures and the launch of generic and pipeline competitors will dampen the growth of certain brands

Monoclonal antibody targeted therapy cancer brands achieved higher sales than small molecule agents in 2007 and will remain the leading class over the forecast period. This is driven by the considerable success of the monoclonal antibody brands Avastin, Herceptin and Rituxan

Key reasons to read this report:

• Quantify the performance of each of the marketed targeted therapy cancer brands in the seven major markets over the period 2007 to 2017
• Assess the changing key opportunities and threats both for currently marketed and pipeline targeted therapy cancer brands
• Identify the leading brands in this market over the next 10 years and understand the key factors driving their success

Table of Contents

ABOUT DATAMONITOR HEALTHCARE 2
About the Oncology pharmaceutical analysis team 2

CHAPTER 1 EXECUTIVE SUMMARY 3
Strategic scoping and focus 3
Datamonitor insight into the targeted therapy cancer brands market 4
Related reports 5
Upcoming reports 5

CHAPTER 2 MARKET DEFINITION 8
Definition of the cancer market by ATC class 8
Molecular targeted therapies 9
L1X3 – Antineoplastic monoclonal antibodies 9
L1X9 – All other antineoplastics 9

CHAPTER 3 MARKET OVERVIEW AND FORECASTS 10
Seven major markets 10
Current market assessment 10
Sales by class 10
Sales by brand 12
Sales by country 15
Future market assessment 17
Sales by class 17
Sales by brand 19
Sales by country 24
Opportunities and threats 28

US 29
Current market assessment 29
Sales by class 29
Sales by brand 31
Future market assessment 32
Sales by class 32
Sales by brand 35

Japan 38
Current market assessment 38
Sales by class 38
Sales by brand 40
Future market assessment 41
Sales by class 41
Sales by brand 44

5EU 47
Current market assessment 47
Sales by class 47
Sales by brand 49
Future market assessment 50
Sales by class 50
Sales by brand 53

France 56
Current market assessment 56
Sales by class 56
Sales by brand 58
Future market assessment 59
Sales by class 59
Sales by brand 62

Germany 65
Current market assessment 65
Sales by class 65
Sales by brand 67
Future market assessment 68
Sales by class 68
Sales by brand 71

Italy 74
Current market assessment 74
Sales by class 74
Sales by brand 76
Future market assessment 77
Sales by class 77
Sales by brand 80

Spain 83

Current market assessment 83
Sales by class 83
Sales by brand 85
Future market assessment 86
Sales by class 86
Sales by brand 89

UK 92
Current market assessment 92
Sales by class 92
Sales by brand 94
Future market assessment 95
Sales by class 95
Sales by brand 98

Rest of World snapshot 101
Current market assessment 101
Global monoclonal antibody brand market 103
Global small molecule brand market 105

CHAPTER 4 BRAND DYNAMICS 107
Brand analysis by class 107
Seven major markets 108
Analysis of current market 108
Analysis of future market 109

US 112
Analysis of current market 112
Analysis of future market 114

Japan 116
Analysis of current market 116
Analysis of future market 118

5EU 120
Analysis of current market 120
Analysis of future market 122

France 124
Analysis of current market 124
Analysis of future market 126

Germany 128
Analysis of current market 128
Analysis of future market 130

Italy 132
Analysis of current market 132
Analysis of future market 134

Spain 136
Analysis of current market 136
Analysis of future market 138

UK 140
Analysis of current market 140
Analysis of future market 142

Brand analysis by approval date144
Since 2005, 10 new targeted therapies have reached the market 144
Brand analysis by indication 145
Solid tumors versus hematological malignancies 145
Targeted therapy cancer brands approved for solid tumors had the highest market share and showed the largest growth in 2007 145
Targeted therapy cancer brands approved for solid tumors will gain even more market share by 2017 146
Analysis of brand by number of approved indications 147
Avastin is the leading targeted therapy cancer brand in terms of the number of approved indications 147
Analysis of indication by number of approved targeted therapies 150
Non-Hodgkin’s lymphoma is the indication with the most approved targeted therapy cancer brands 150
Brand analysis by mode of administration 152
Intravenously administered targeted therapy cancer brands have the greatest market share 152
Brand analysis by company 154
23 different companies are involved in the marketing of targeted therapy cancer brands in the seven major markets 154
Co-marketed targeted therapy cancer brands have the largest market share in 2007 156
Brand analysis by event 157
Avastin will experience the greatest number of forecast events across the seven major markets 157

CHAPTER 5 BRAND PROFILES AND FORECASTS 159

Avastin 159
Brand profile 159
Brand forecast events 161
Brand forecast to 2017 162
Avastin set to become the biggest-selling targeted therapy cancer brand in the seven major markets in 2009 163

Bexxar 164
Brand profile 164
Brand forecast events 165
Brand forecast to 2017 165

Campath 166
Brand profile 166
Brand forecast events 167
Brand forecast to 2017 168

Erbitux 169
Brand profile 169
Brand forecast events 170
Brand forecast to 2017 171
Erbitux seven major market sales passed $1 billion in 2007 and are set for modest growth through line extensions and new approvals 171

Gleevec 173
Brand profile 173
Brand forecast events 174
Brand forecast to 2017 175
Patent expiries across the seven major markets will curb long-term growth of Gleevec sales 175

Herceptin 177
Brand profile 177
Brand forecast events 178
Brand forecast to 2017 179
Herceptin well placed to maintain strong performance in breast cancer market 179

Iressa 181
Brand profile 181
Brand forecast events 182
Brand forecast to 2017 183
Iressa’s declining sales could experience a turnaround following new Phase III lung cancer trial 183

Mylotarg 185
Brand profile 185
Brand forecast events 186
Brand forecast to 2017 186

Nexavar 187
Brand profile 187
Brand forecast events 188
Brand forecast to 2017 189
Liver cancer approval will help Nexavar to make up for disappointing performance in RCC market 189

Ontak 191
Brand profile 191
Brand forecast events 192
Brand forecast to 2017 192

Revlimid 193
Brand profile 193
Brand forecast events 194
Brand forecast to 2017 195
First-line multiple myeloma approval will allow Revlimid to reach sales of $1 billion in the seven major markets by 2015 195

Rituxan 197
Brand profile 197
Brand forecast events 198
Brand forecast to 2017 199
Rituxan was the biggest-selling targeted therapy cancer brand in 2007 199

Sprycel 201
Brand profile 201
Brand forecast events 202
Brand forecast to 2017 203
Generic imatinib and competition from Tasigna will limit Sprycel’s uptake in first-line CML 203

Sutent 204
Brand profile 204
Brand forecast events 205
Brand forecast to 2017 206
Indication expansion will enable Sutent to become the leading small molecule targeted therapy cancer brand in 2017 206

Tarceva 208
Brand profile 208
Brand forecast events 209
Brand forecast to 2017 210
Additional lung cancer approvals will help drive growth of Tarceva sales 210

Targretin 212
Brand profile 212
Brand forecast events 213
Brand forecast to 2017 214

Tasigna 215
Brand profile 215
Brand forecast events 216
Brand forecast to 2017 217
Tasigna is well-positioned to compensate for Gleevec patent expiry 217

Thalomid 219
Brand profile 219
Brand forecast events 220
Brand forecast to 2017 221

Torisel 222
Brand profile 222
Brand forecast events 223
Brand forecast to 2017 224

Tykerb 225
Brand profile 225
Brand forecast events 226
Brand forecast to 2017 227
Breast cancer line extensions will push Tykerb sales beyond $1.4 billion in the seven major markets by 2017 227

Vectibix 229
Brand profile 229
Brand forecast events 230
Brand forecast to 2017 231
Vectibix is set to lag behind Erbitux and Avastin in the colorectal cancer market 231

Velcade 233
Brand profile 233
Brand forecast events 234
Brand forecast to 2017 235
Velcade seven major market sales will reach $1 billion by 2010 following approval for first-line multiple myeloma 235

Zevalin 237
Brand profile 237
Brand forecast events 238
Brand forecast to 2017 239

Zolinza 240
Brand profile 240
Brand forecast events 241
Brand forecast to 2017 242

APPENDIX A – MARKET ASSUMPTIONS 243
Country-specific assumptions and events 243

• Effect of Medicare Modernization Act in the US 243
• Biennial price cuts in Japan 243
• Generic erosion assumptions 243

Data definitions, limitations and assumptions 244

• Standard units 244
• Japanese market data 244
• Derivation of sales forecasts and pricing trends 244

Forecasts 245
Forecast methodology 245

APPENDIX B 246
Bibliography 246
List of figures 251
Abbreviations 252
Report methodology 254
About Datamonitor 254

• About Datamonitor Healthcare 254
• Disclaimer 256

List of Tables
Table 1: Definition of the cancer market by ATC class, 2008 8

Table 2: Seven major market sales of targeted therapy cancer brands by drug class, 2007 10

Table 3: Seven major market sales of targeted therapy cancer brands, 2007 12

Table 4: Individual country sales of targeted therapy cancer brands, 2007 16

Table 5: Seven major market forecast sales of targeted therapy cancer brands by drug class ($m), 2007-2017 18

Table 6: Seven major market forecast sales of targeted therapy cancer brands ($m), 2007-2017 20

Table 7: Individual country forecast sales of targeted therapy cancer brands ($m) in the seven major markets, 2007-2017 25

Table 8: US sales of targeted therapy cancer brands by drug class, 2007 29

Table 9: US sales of targeted therapy cancer brands, 2007 31

Table 10: US forecast sales of targeted therapy cancer brands by drug class ($m), 2007-2017 32

Table 11: US forecast sales of targeted therapy cancer brands ($m), 2007-2017 35

Table 12: Japan sales of targeted therapy cancer brands by drug class, 2007 38

Table 13: Japan sales of targeted therapy cancer brands, 2007 40

Table 14: Japan forecast sales of targeted therapy cancer brands by drug class ($m), 2007-2017 41

Table 15: Japan forecast sales of targeted therapy cancer brands ($m), 2007-2017 44

Table 16: 5EU sales of targeted therapy cancer brands by drug class, 2007 47

Table 17: 5EU sales of targeted therapy cancer brands, 2007 49

Table 18: 5EU forecast sales of targeted therapy cancer brands by drug class ($m), 2007-2017 50

Table 19: 5EU forecast sales of targeted therapy cancer brands ($m), 2007-2017 53

Table 20: France sales of targeted therapy cancer brands by drug class, 2007 56

Table 21: France sales of targeted therapy cancer brands, 2007 58

Table 22: France forecast sales of targeted therapy cancer brands by drug class ($m), 2007-2017 59

Table 23: France forecast sales of targeted therapy cancer brands ($m), 2007-2017 62

Table 24: Germany sales of targeted therapy cancer brands by drug class, 2007 65

Table 25: Germany sales of targeted therapy cancer brands, 2007 67

Table 26: Germany forecast sales of targeted therapy cancer brands by drug class ($m), 2007-2017 68

Table 27: Germany forecast sales of targeted therapy cancer brands ($m), 2007-2017 71

Table 28: Italy sales of targeted therapy cancer brands by drug class, 2007 74

Table 29: Italy sales of targeted therapy cancer brands, 2007 76

Table 30: Italy forecast sales of targeted therapy cancer brands by drug class ($m), 2007-2017 77

Table 31: Italy forecast sales of targeted therapy cancer brands ($m), 2007-2017 80

Table 32: Spain sales of targeted therapy cancer brands by drug class, 2007 83

Table 33: Spain sales of targeted therapy cancer brands, 2007 85

Table 34: Spain forecast sales of targeted therapy cancer brands by drug class ($m), 2007-2017 86

Table 35: Spain forecast sales of targeted therapy cancer brands ($m), 2007-2017 89

Table 36: UK sales of targeted therapy cancer brands by drug class, 2007 92

Table 37: UK sales of targeted therapy cancer brands, 2007 94

Table 38: UK forecast sales of targeted therapy cancer brands by drug class ($m), 2007-2017 95

Table 39: UK forecast sales of targeted therapy cancer brands ($m), 2007-2017 98

Table 40: US, Japan, 5EU and RoW targeted therapy cancer brand sales, 2007 101

Table 41: US, Japan, 5EU and RoW monoclonal antibodies targeted therapy cancer brand sales, 2007 103

Table 42: US, Japan, 5EU and RoW small molecule targeted therapy cancer brand markets, 2007 105

Table 43: Classification of targeted therapy cancer brands, 2008 107

Table 44: Seven major market sales of targeted therapy cancer brands by drug subclass ($m), 2007 108

Table 45: Seven major market forecast sales of targeted therapy cancer brands by drug subclass ($m), 2017 110

Table 46: US sales of targeted therapy cancer brands by drug subclass ($m), 2007 112

Table 47: US forecast sales of targeted therapy cancer brands by drug subclass ($m), 2017 114

Table 48: Japan sales of targeted therapy cancer brands by drug subclass ($m), 2007 116

Table 49: Japan forecast sales of targeted therapy cancer brands by drug subclass ($m), 2017 118

Table 50: 5EU sales of targeted therapy cancer brands by drug subclass ($m), 2007 120

Table 51: 5EU forecast sales of targeted therapy cancer brands by drug subclass ($m), 2017 122

Table 52: France sales of targeted therapy cancer brands by drug subclass ($m), 2007 124

Table 53: France forecast sales of targeted therapy cancer brands by drug subclass ($m), 2017 126

Table 54: Germany sales of targeted therapy cancer brands by drug subclass ($m), 2007 128

Table 55: Germany forecast sales of targeted therapy cancer brands by drug subclass ($m), 2017 130

Table 56: Italy sales of targeted therapy cancer brands by drug subclass ($m), 2007 132

Table 57: Italy forecast sales of targeted therapy cancer brands by drug subclass ($m), 2017 134

Table 58: Spain sales of targeted therapy cancer brands by drug subclass ($m), 2007 136

Table 59: Spain forecast sales of targeted therapy cancer brands by drug subclass ($m), 2017 138

Table 60: UK sales of targeted therapy cancer brands by drug subclass ($m), 2007 140

Table 61: UK forecast sales of targeted therapy cancer brands by drug subclass ($m), 2017 142

Table 62: Approved oncology indications for monoclonal antibody targeted therapy cancer brands in US, 5EU and Japan, 2008 147

Table 63: Approved oncology indications for small molecule targeted therapy cancer brands in US, 5EU and Japan, 2008 148

Table 64: Avastin: key facts 160

Table 65: Avastin: brand forecast events 161

Table 66: Avastin forecast sales in the seven major markets ($m), 2007-2017 162

Table 67: Bexxar: key facts 164

Table 68: Bexxar: brand forecast events 165

Table 69: Bexxar forecast sales in the seven major markets ($m), 2007-2017 165

Table 70: Campath: key facts 166

Table 71: Campath: brand forecast events 167

Table 72: Campath forecast sales in the seven major markets ($m), 2007-2017 168

Table 73: Erbitux: key facts 169

Table 74: Erbitux: brand forecast events 170

Table 75: Erbitux forecast sales in the seven major markets ($m), 2007-2017 171

Table 76: Gleevec: key facts 173

Table 77: Gleevec: brand forecast events 174

Table 78: Gleevec forecast sales in the seven major markets ($m), 2007-2017 175

Table 79: Herceptin: key facts 177

Table 80: Herceptin: brand forecast events 178

Table 81: Herceptin forecast sales in the seven major markets ($m), 2007-2017 179

Table 82: Iressa: key facts 181

Table 83: Iressa: brand forecast events 182

Table 84: Iressa forecast sales in the seven major markets ($m), 2007-2017 183

Table 85: Mylotarg: key facts 185

Table 86: Mylotarg forecast sales in the seven major markets ($m), 2007-2017 186

Table 87: Nexavar: key facts 187

Table 88: Nexavar: brand forecast events 188

Table 89: Nexavar forecast sales in the seven major markets ($m), 2007-2017 189

Table 90: Ontak: key facts 191

Table 91: Ontak: brand forecast events 192

Table 92: Ontak forecast sales in the seven major markets ($m), 2007-2017 192

Table 93: Revlimid: key facts 193

Table 94: Revlimid: brand forecast events 194

Table 95: Revlimid forecast sales in the seven major markets ($m), 2007-2017 195

Table 96: Rituxan: key facts 197

Table 97: Rituxan: brand forecast events 198

Table 98: Rituxan forecast sales in the seven major markets ($m), 2007-2017 199

Table 99: Sprycel: key facts 201

Table 100: Sprycel: brand forecast events 202

Table 101: Sprycel forecast sales in the seven major markets ($m), 2007-2017 203

Table 102: Sutent: key facts 204

Table 103: Sutent: brand forecast events 205

Table 104: Sutent forecast sales in the seven major markets ($m), 2007-2017 206

Table 105: Tarceva: key facts 208

Table 106: Tarceva: brand forecast events 209

Table 107: Tarceva forecast sales in the seven major markets ($m), 2007-2017 210

Table 108: Targretin: key facts 212

Table 109: Targretin: brand forecast events 213

Table 110: Targretin forecast sales in the seven major markets ($m), 2007-2017 214

Table 111: Tasigna: key facts 215

Table 112: Tasigna: brand forecast events 216

Table 113: Tasigna forecast sales in the seven major markets ($m), 2007-2017 217

Table 114: Thalomid: key facts 219

Table 115: Thalomid: brand forecast events 220

Table 116: Thalomid forecast sales in the seven major markets ($m), 2007-2017 221

Table 117: Torisel: key facts 222

Table 118: Torisel: brand forecast events 223

Table 119: Torisel forecast sales in the seven major markets ($m), 2007-2017 224

Table 120: Tykerb: key facts 225

Table 121: Tykerb: brand forecast events 226

Table 122: Tykerb forecast sales in the seven major markets ($m), 2007-2017 227

Table 123: Vectibix: key facts 229

Table 124: Vectibix: brand forecast events 230

Table 125: Vectibix forecast sales in the seven major markets ($m), 2007-2017 231

Table 126: Velcade: key facts 233

Table 127: Velcade: brand forecast events 234

Table 128: Velcade forecast sales in the seven major markets ($m), 2007-2017 235

Table 129: Zevalin: key facts 237

Table 130: Zevalin: brand forecast events 238

Table 131: Zevalin forecast sales in the seven major markets ($m), 2007-2017 239

Table 132: Zolinza: key facts 240

Table 133: Zolinza: brand forecast events 241

Table 134: Zolinza forecast sales in the seven major markets ($m), 2007-2017 242

Table 135: Abbreviations used in Commercial Insight: Targeted therapy cancer brands 252

List of Figures
Figure 1: Seven major market sales and market share of targeted therapy cancer brands by drug class, 2007 11

Figure 2: Seven major market sales and market share of monoclonal antibody targeted therapy cancer brands, 2007 14

Figure 3: Seven major market sales and market share of small molecule targeted therapy cancer brands, 2007 15

Figure 4: Individual country sales and market share of targeted therapy cancer brands, 2007 17

Figure 5: Seven major market forecast sales of targeted therapy cancer brands by drug class ($m), 2007-2017 18

Figure 6: Seven major market forecast sales and market share of targeted therapy cancer brands by drug class ($m), 2017 19

Figure 7: Seven major market forecast sales of monoclonal antibody targeted therapy cancer brands ($m), 2007-2017 21

Figure 8: Seven major market forecast sales and market share of monoclonal antibody targeted therapy cancer brands, 2017 22

Figure 9: Seven major market forecast sales of small molecule targeted therapy cancer brands ($m), 2007-2017 23

Figure 10: Seven major market forecast sales and market share of small molecule targeted therapy cancer brands, 2017 24

Figure 11: Individual country forecast sales of targeted therapy cancer brands ($m) in the seven major markets, 2007-2017 26

Figure 12: Individual country forecast sales and market share of targeted therapy cancer brands in the seven major markets, 2017 27

Figure 13: Summary of opportunities and threats for targeted therapy cancer brands in the seven major markets 28

Figure 14: US sales of targeted therapy cancer brands by drug class, 2007 30

Figure 15: US forecast sales of targeted therapy cancer brands by drug class ($m), 2007-2017 33

Figure 16: US forecast sales and market share of targeted therapy cancer brands by drug class ($m), 2017 34

Figure 17: US forecast sales of monoclonal antibody targeted therapy cancer brands ($m), 2007-2017 36

Figure 18: US forecast sales of small molecule targeted therapy cancer brands ($m), 2007-2017 37

Figure 19: Japan sales and market share of targeted therapy cancer brands by drug class, 2007 39

Figure 20: Japan forecast sales of targeted therapy cancer brands by drug class ($m), 2007-2017 42

Figure 21: Japan forecast sales and market share of targeted therapy cancer brands by drug class ($m), 2017 43

Figure 22: Japan forecast sales of monoclonal antibody targeted therapy cancer brands ($m), 2007-2017 45

Figure 23: Japan forecast sales of small molecule targeted therapy cancer brands ($m), 2007-2017 46

Figure 24: 5EU sales and market share of targeted therapy cancer brands by drug class, 2007 48

Figure 25: 5EU forecast sales of targeted therapy cancer brands by drug class ($m), 2007-2017 51

Figure 26: 5EU forecast sales and market share of targeted therapy cancer brands by drug class ($m), 2017 52

Figure 27: 5EU forecast sales of monoclonal antibody targeted therapy cancer brands ($m), 2007-2017 54

Figure 28: 5EU forecast sales of small molecule targeted therapy cancer brands ($m), 2007-2017 55

Figure 29: France sales and market share of targeted therapy cancer brands by drug class, 2007 57

Figure 30: France forecast sales of targeted therapy cancer brands by drug class ($m), 2007-2017 60

Figure 31: France forecast sales and market share of targeted therapy cancer brands by drug class ($m), 2017 61

Figure 32: France forecast sales of monoclonal antibody targeted therapy cancer brands ($m), 2007-2017 63

Figure 33: France forecast sales of small molecule targeted therapy cancer brands ($m), 2007-2017 64

Figure 34: Germany sales and market share of targeted therapy cancer brands by drug class, 2007 66

Figure 35: Germany forecast sales of targeted therapy cancer brands by drug class ($m), 2007-2017 69

Figure 36: Germany forecast sales and market share of targeted therapy cancer brands by drug class ($m), 2017 70

Figure 37: Germany forecast sales of monoclonal antibody targeted therapy cancer brands ($m), 2007-2017 72

Figure 38: Germany forecast sales of small molecule targeted therapy cancer brands ($m), 2007-2017 73

Figure 39: Italy sales and market share of targeted therapy cancer brands by drug class, 2007 75

Figure 40: Italy forecast sales of targeted therapy cancer brands by drug class ($m), 2007-2017 78

Figure 41: Italy forecast sales and market share of targeted therapy cancer brands by drug class ($m), 2017 79

Figure 42: Italy forecast sales of monoclonal antibody targeted therapy cancer brands ($m), 2007-2017 81

Figure 43: Italy forecast sales of small molecule targeted therapy cancer brands ($m), 2007-2017 82

Figure 44: Spain sales and market share of targeted therapy cancer brands by drug class, 2007 84

Figure 45: Spain forecast sales of targeted therapy cancer brands by drug class ($m), 2007-2017 87

Figure 46: Spain forecast sales and market share of targeted therapy cancer brands by drug class ($m), 2017 88

Figure 47: Spain forecast sales of monoclonal antibody targeted therapy cancer brands ($m), 2007-2017 90

Figure 48: Spain forecast sales of small molecule targeted therapy cancer brands ($m), 2007-2017 91

Figure 49: UK sales and market share of targeted therapy cancer brands by drug class, 2007 93

Figure 50: UK forecast sales of targeted therapy cancer brands by drug class ($m), 2007-2017 96

Figure 51: UK forecast sales and market share of targeted therapy cancer brands by drug class ($m), 2017 97

Figure 52: UK forecast sales of monoclonal antibody targeted therapy cancer brands ($m), 2007-2017 99

Figure 53: UK forecast sales of small molecule targeted therapy cancer brands ($m), 2007-2017 100

Figure 54: US, Japan, 5EU and RoW targeted therapy cancer brand sales and market share, 2007 102

Figure 55: US, Japan, 5EU and RoW monoclonal antibodies targeted therapy cancer brand sales and market share, 2007 104

Figure 56: Sales performance of the US, Japan, 5EU and RoW small molecule targeted therapy cancer brand sales and market share, 2007 106

Figure 57: Seven major market sales and market share of targeted therapy cancer brands by drug subclass ($m), 2007 109

Figure 58: Seven major market forecast sales and market share of targeted therapy cancer brands by drug subclass ($m), 2017 111

Figure 59: US sales and market share of targeted therapy cancer brands by drug subclass ($m), 2007 113

Figure 60: US forecast sales and market share of targeted therapy cancer brands by drug subclass ($m), 2017 115

Figure 61: Japan sales and market share of targeted therapy cancer brands by drug subclass ($m), 2007 117

Figure 62: Japan forecast sales and market share of targeted therapy cancer brands by drug subclass ($m), 2017 119

Figure 63: 5EU sales and market share of targeted therapy cancer brands by drug subclass ($m), 2007 121

Figure 64: 5EU forecast sales and market share of targeted therapy cancer brands by drug subclass ($m), 2017 123

Figure 65: France sales and market share of targeted therapy cancer brands by drug subclass ($m), 2007 125

Figure 66: France forecast sales and market share of targeted therapy cancer brands by drug subclass ($m), 2017 127

Figure 67: Germany sales and market share of targeted therapy cancer brands by drug subclass ($m), 2007 129

Figure 68: Germany forecast sales and market share of targeted therapy cancer brands by drug subclass ($m), 2017 131

Figure 69: Italy sales and market share of targeted therapy cancer brands by drug subclass ($m), 2007 133

Figure 70: Italy forecast sales and market share of targeted therapy cancer brands by drug subclass ($m), 2017 135

Figure 71: Spain sales and market share of targeted therapy cancer brands by drug subclass ($m), 2007 137

Figure 72: Spain forecast sales and market share of targeted therapy cancer brands by drug subclass ($m), 2017 139

Figure 73: UK sales and market share of targeted therapy cancer brands by drug subclass ($m), 2007 141

Figure 74: UK forecast sales and market share of targeted therapy cancer brands by drug subclass ($m), 2017 143

Figure 75: First approval dates of targeted therapy cancer brands in the seven major markets, 1996-2007 144

Figure 76: Seven major market sales of targeted therapy cancer brands by type of indication ($m), 2007 145

Figure 77: Seven major market forecast sales of targeted therapy cancer brands by type of indication ($m), 2017 146

Figure 78: Analysis of targeted therapy cancer brands by number of approved oncology indications in the seven major markets, 2008 149

Figure 79: Analysis of oncology indications by number of approved targeted therapy cancer brands in the seven major markets, 2008 150

Figure 80: Seven major market sales of targeted therapy cancer brands by mode of administration ($m), 2007 152

Figure 81: Seven major market forecast sales of targeted therapy cancer brands by mode of administration ($m), 2017 153

Figure 82: Analysis of companies by number of approved targeted therapy cancer brands in the seven major markets, 2008 155

Figure 83: Seven major market sales of targeted therapy cancer brands marketed by single companies versus targeted therapy cancer brands marketed by more than one company, 2007 156

Figure 84: Analysis of targeted therapy cancer brands by number of forecast events, 2008-2017 158